CATEGORIES: Research
drug discovery

CMT Research Update: The Drug Discovery Process

by | Aug 6, 2014 | 5 comments

drug discovery

A recent, informative article from the MDA outlined the process for drug discovery and bringing a drug to market. What’s striking is the length of this process, particularly within the context of the search for a cure for Charcot-Marie-Tooth.

Once a drug appears to work effectively in mice, it must undergo further testing before it can be used on humans in clinical trials. Over an approximate two year period, researchers work to determine if that drug has the best chance of having the desired effect on the disease with the lowest possible harm to the patient. Then toxicology studies must be done to show the U.S. Food and Drug Administration (FDA) that the drug is safe and likely to be effective. Further they must determine how to administer the drug and at what dosage. This preclinical research takes five to seven years and costs millions of dollars.

Once the preclinical research is satisfied, researchers can petition the FDA for approval to start clinical trials. This is when the drug is used on humans. Clinical trials can take another five to seven years to complete. Only when the clinical trials have finished with positive results can researchers request approval (from the FDA) to market a drug. Simply put, “on average it takes a drug about 12 years to get from discovery to market and it costs about $1.8 billion per drug that works,” according to the article.

It is because research is such a lengthy process that HNF’s TRIAD (Therapeutic Research in Accelerated Discovery) is so important.   Our three-prong approach includes

1) Clinical Therapeutics: research that will lead to improved therapies and a better quality of life for people with CMT right now, including studies on bracing, exercise, surgery, and mental health strategies;

2) Basic Science: research that will lead to a greater understanding of CMT,  including translational research not yet applied to CMT; and

3) Drug Discovery: research that has considerable potential to produce a cure for CMT.

We believe that this multi-tiered approach will best support people with CMT while we work to develop effective therapies, treatments and a cure for CMT.

What can we do right now while we are waiting? The single most important thing for everyone is of course to keep moving, both mind and body!  Whatever level you’re at, keep exercising, stay tuned in, read all the latest news at HNF and the National CMT Resource Center.

Learn more on this topic

Related Blog Posts

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Sneak Peak of Fall Newsletter: CMT Research Study Survey

My name is Elizabeth Francisco and I am a graduate student from the Genetic Counseling program at the University of North Carolina Greensboro. I am inviting you to participate in a research study. The goal of my study is to learn more about the experiences of people with Charcot-Marie-Tooth (CMT) with genetic counseling and genetic testing. Adults with CMT and parents or legal guardians of someone of any age who has a diagnosis of CMT are eligible to participate

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

Quality of Life and CMT Research

Did you know that 95% of clinical trials fail? There are multiple causes, most related to efficacy or safety, which obviously can be harmful and risky for patients. The risk-reward of enrolling in trials is a judgment call based on the devastating effects of disease related to quality of life (QoL) or life-threatening disease. With CMT, the risk-reward is more of a challenging question for many, as CMT in most cases is non-fatal.

Help us answer questions that your doctors and the CMT Research Community aren’t too sure about.

Did you know that you can become part of a community in therapy development and further research for all forms of CMT and inherited neuropathies? The mission of the Global Registry for Inherited neuropathies (GRIN) is to collect clinical and genetic information from patients with ALL forms of Charcot-Marie-Tooth (CMT) and other related rare and ultra rare inherited neuropathies.

Hot off the press

It seems like almost weekly there is another new publication on CMT with interesting basic biology. While an earlier “Hot off the press” highlighted the work of Cherry and co-workers at the University of Texas Southwestern Medical Center who showed show that neurons lacking a gene for rab7 result in neuropathy.

New Study on CMT Type 2B

If we are to learn more about CMT and the effectiveness of rehabilitation it is worth asking the patient and their caregiver. A recent Italian study by Padua et al recently described a survey of CMT patients and caregivers and their perspectives and perceptions of rehabilitation efficacy and needs.

Allison Moore is going to be published!

HNF’s CSO (Chief Scientific Officer), Sean Ekins wrote a blog about his work with Allison Moore and her two “fighter Mom” friends Lori Sames and Jill Wood. He named his blog: “Rare disease heroes – Extraordinary collaborators we should be listening too.” Sean helped my friends and I write a paper called: “Multifaceted roles of ultra rare and rare disease patients/parents in drug discovery.” YES, Allison Moore is going to be published! It will be in Drug Discovery Today, soon. The link to the reprint is below.

Join the conversation

Leave a Comment

5 Comments

  1. mickgaffney

    HELLO THERE , i live in australia and have been diagnosed with cmt and try as much as i can
    too keep myself fit and active i hear they have a drug called pxt 3003 in america and europe and it has had a lot of success with cmt im trying too find out if i can get this happening here in australia
    no one here can help me here that knows anything about this medicine does anyone know about theses trails that are going on over there. CHEERS MICK

    Reply
  2. Clyde D Wheeler

    Hi, My name is Clyde & I was diagnosed with CMT at John’s Hopkins in 2005. Is it possible that the COVID 19 vaccine will have an impact on identifying possible defects & cures in DNA ?

    Reply
  3. Rosa

    Hi my name is Rosa iam 68 years old and i just got diegnosed with CMT Please contact me on my email i want to know how many people got this and how are you coping with this problem

    Reply
    • Estela Lugo

      Hi Rosa, There are approximately 2.6 million people living in the world with CMT. For more information please comb through our website under patient resources as well as our many webinars across a wide variety of CMT-related topics.

      Reply
  4. kristina

    we need research for CMT4C more than anything in our lives….our boys are 8 and 12 and quickly decling.

    Reply

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news